ReviewChemistry, an Asian journal2026
Recent Advances in Zinc(II)-Complexes for Antibacterial Photodynamic Therapy.
Review in Chemistry, an Asian journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antimicrobial resistance (AMR) has emerged as a global health crisis, underlining the need for alternative therapeutic strategies beyond conventional antibiotics. In this regard, antibacterial photodynamic therapy (aPDT) has gained increasing attention as a non-invasive approach that utilizes light-activated photosensitizers to generate targeted reactive oxygen species (ROS), leading to rapid bacterial inactivation with minimal resistance development. Among various photosensitizers, Zn(II) complexes have shown promising potential due to their favorable biocompatibility, photophysical properties, and tunable coordination chemistry. Unlike heavy-metal photosensitizers, Zn(II) complexes owe their photophysical performance to extended macrocyclic π-systems rather than metal spin-orbit coupling, making them uniquely suited for biocompatible aPDT. This review critically examines recent advances in Zn(II)-based complexes as photosensitizers, including phthalocyanines, porphyrins, chlorins, and curcumin systems, highlighting structure-activity relationships (SARs), ROS generation mechanisms, and antibacterial efficacy against both Gram-positive and Gram-negative pathogens, including multidrug-resistant strains. Key design strategies such as cationic functionalization, polymer conjugation, and hybridization with antimicrobial peptides are discussed. Additionally, current limitations, including aggregation, limited penetration, translational challenges, and future perspectives for clinical translation are also outlined. This review aims to provide a comprehensive framework for the rational design of next-generation Zn(II)-photosensitizers for effective aPDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.